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Abstract
 
Peptide acquisition by MHC class II molecules is catalyzed by HLA-DM (DM). In B cells,
HLA-DO (DO) inhibits or modifies the peptide exchange activity of DM. We show here that
DO protein levels are modulated during B cell differentiation. Remarkably, germinal center
(GC) B cells, which have low levels of DO relative to naive and memory B cells, are shown to
have enhanced antigen presentation capabilities. DM protein levels also were somewhat re-
duced in GC B cells; however, the ratio of DM to DO in GC B cells was substantially in-
creased, resulting in more free DM in GC B cells. We conclude that modulation of DM and
DO in distinct stages of B cell differentiation represents a mechanism by which B cells regulate
their capacity to function as antigen-presenting cells. Efficient antigen presentation in GC B
cells would promote GC B cell–T cell interactions that are essential for B cells to survive posi-
tive selection in the GC.
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Introduction
 
Recognition of antigen by CD4
 
 
 
 T cells requires the pre-
sentation of short, pathogen-derived peptides displayed in
the binding groove of MHC class II molecules (1). Class II
molecules assemble in the endoplasmic reticulum and are
transported via the Golgi apparatus to endocytic organelles
where they are loaded with peptide cargo (2). Peptide load-
ing of class II molecules is directly catalyzed by the action of
a class II-like molecule, DM, which also acts as a peptide
editor (3). Whereas class II and DM molecules are ex-
pressed by all professional APC, the class II-like molecule,
DO, is expressed only in B cells and thymic epithelium (4).
DO physically associates with DM in the endoplasmic
reticulum during and after transport to class II-positive en-
docytic organelles (5). Recent evidence indicates that the
association of DO with DM impairs or alters the peptide
exchange activity of DM (4, 6–9), leading to increased lev-
els of cell surface class II–class II-associated invariant chain
peptides (CLIP) and reduced levels of class II-peptide (6, 8).
The unique expression of DO in B cells suggests that
DO plays a role in presentation of antigens recognized by
T cells during cognate interactions. The precise molecular
function of DO in B cells remains to be elucidated. To
define a role for DO in human B cells, we analyzed DO
expression during the course of B cell activation. Using
primary tonsillar B cells, we determined that DO is down-
modulated in B cells upon entry into the GC. GC B cells
had low levels of DO protein relative to naive and memory
B cells. Decreased DO expression was associated with re-
duced levels of cell surface class II-CLIP and increased
surface class II-peptide. These data suggest that B cells
modulate their antigen-processing capabilities during dif-
ferentiation by altering DO levels.
 
Materials and Methods
 
Cell Lines.
 
T2, Pala, and Raji cells were maintained in Is-
cove’s DME with 5–10% calf serum as described (10).
 
Antibodies.
 
Anti–human mAbs used for FACS analyses were
as follows: mouse IgG1-FITC (isotype control), PE-conjugated
anti-CD19 and -CD38, Cy-Chrome
 
®
 
 (Cyc) and allophycoeryth-
rin-conjugated anti-CD38 and biotinylated anti-CD80 (B7.1)
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and -CD86 (B7.2) (all obtained from BD PharMingen). FITC-
and PE-conjugated anti-IgD and -IgG (Southern Biotech). Bio-
tinylated mAbs were detected with Streptavidin-CyC (BD Phar-
Mingen). Purified mAbs used for T cell depletions, anti-CD3
(OKT-3), -CD4 (Leu3a) and -CD8 (OKT-8), were purchased
from the mAb Core Facility at Memorial Sloan-Kettering Cancer
Center (MSKCC). The following mAbs were purified from
bioreactor supernatants using standard protein G–Sepharose (Am-
ersham Pharmacia Biotech) or protein A–Sepharose (Sigma-
Aldrich) affinity chromatography: Mags.DO5, MaP.DM1 (6),
L243 (11), CerCLIP.1 (11), and 3D3 (12), and conjugated with
FITC or biotin as described previously (13).
To produce anti-human DO mAbs, mice were immunized
with affinity-purified DM–DO complexes (10) emulsified in Ti-
ter Max (CytRx Corp.) and screened for an immune response
by ELISA. Splenocytes were fused to SP2/O-Ag14 cells, and
culture supernatants from the hybridoma cells were screened by
immunofluorescence using DO positive and negative B cells.
One hybridoma secreted an mAb that recognized DO. This
clone (Mags.DO5; IgG1), recognizes free DO in addition to
DM–DO complexes.
 
Tonsillar Samples and Cell Isolation.
 
Surplus sections of fresh
human tonsillar specimens were processed in the Department of
Pathology (The New York Presbyterian Hospital) and used ac-
cording to an IRB-approved protocol. Before FACS analysis,
tonsillar samples were T-depleted by application of anti-CD3,
-CD4 and -CD8 mAbs, followed by addition of magnetic beads
(BioMag) coupled with anti–mouse IgG (Polysciences, Inc.). Al-
ternatively, B cells were positively selected with anti-CD19 mi-
crobeads (Miltenyi Biotech).
 
FACS Analyses and Cell Sorting.
 
Tonsillar samples were
stained for FACS analyses as previously described (14) and ana-
lyzed using an LSR flow cytometer (Becton Dickinson). For intra-
cellular staining, samples were incubated with antibodies specific
for surface proteins, fixed and permeabilized with Cytofix/Cyto-
perm (BD PharMingen), and stained according to the supplied
protocol. To sort naive and GC B cell populations, T cell–depleted
tonsillar cells were stained with anti–CD38-PE and –IgD-FITC,
washed and sorted with a cell sorter (MoFlo; Cytomation).
 
Statistical Methods.
 
The statistical significance of differences
among results for mean fluorescence intensity (MFI) and expres-
sion ratios were evaluated by the Student’s 
 
t 
 
test, (data analysis
toolpack; Excel). 
 
P
 
 values were determined using the two-tailed 
 
t
 
test for DO, DM, class II, and CLIP, whereas the one-tailed test
used B7.1 and B7.2.
 
Immunoblot Analysis and Quantitation.
 
Cell populations were
extracted in Triton X-100 and SDS-PAGE gels loaded with
threefold dilutions of cell lysates (10
 
6
 
 to 3.7 
 
 
 
 10
 
4
 
 cells/lane). Af-
ter transfer, membranes were incubated with rabbit antibodies to
the cytoplasmic tails of DM
 
 
 
 (R.DMB/c; reference 11) and
DO
 
 
 
 (R.DOB/c; reference 6) or for calnexin (Stressgen), de-
tected with a goat anti–rabbit alkaline-phosphatase reagent (Jack-
son ImmunoResearch Laboratories) and quantitated by fluores-
cence (Vistra ECF; Amersham Pharmacia Biotech) with a
molecular imager FX system and QuantityOne software (Bio-
Rad Laboratories). The percent DO
 
 
 
 or DM
 
 
 
 in naive relative
to GC B cells was calculated as: percent expression 
 
 
 
 (FI
 
GC
 
/
FI
 
Naive
 
) 
 
  
 
100. Analyses were considered valid only if similar val-
ues were obtained at a minimum of two cell equivalents.
 
Real-time PCR.
 
Total RNA was isolated from sorted cells,
cDNA was generated using oligo-dT primers and Real-time
PCR was performed according to the manufacturer’s instruc-
tions (Roche) using the primer pairs: F-DMA, 5
 
 
 
AAA-
 
GCCCATCTGGACATCCTG-3
 
 
 
; R-DMA, 5
 
 
 
AGTGGAAC-
TTGCGGAACAAATG-3
 
 
 
; F-DOB, 5
 
 
 
TCAAGGCACAG-
ACTCTCCAGAAG-3
 
 
 
; R-DOB, 5
 
 
 
CCACAAACATCC-
CCACATCACTG-3
 
 
 
. Raji cDNA was used to generate a
standard curve from which the amount of DNA amplified in
each sample was determined. The ratio of DMA to DOB mes-
sage at four template concentrations was used to calculate rela-
tive DMA/DOB ratios within the naïve or GC B cell popula-
tions.
 
Results
 
GC B Cells Have Characteristics of Efficient APCs.
 
To
examine the status of the class II antigen-processing path-
way in human B cells, we initially measured levels of HLA-
DR (DR) and class II–CLIP complexes on the surface of
naive (IgD
 
 
 
 CD38
 
 
 
), GC (IgD
 
 
 
 CD38
 
 
 
) and memory
(CD38
 
 
 
 IgG
 
 
 
) B cells from fifteen human tonsillar speci-
mens (Fig. 1 A; reference 15). Additionally, the levels of
the costimulatory molecules, B7.1 and B7.2, were deter-
mined. Flow cytometric data for a representative tonsillar
specimen are shown in Fig. 1 B, and the data for all tonsil-
lar specimens are provided in Fig. 2. As expected in a het-
erogeneous set of primary human tissues, cell-surface levels
of each of these proteins varied among the samples. To
compensate, we normalized the signal (MFI) in GC and
memory B cells to that measured in naive B cells of the
same specimen. On average, cell-surface DR on GC B cells
was 
 
 
 
150% of that observed for naive B cells, whereas for
memory B cells, surface DR decreased to 
 
 
 
70% of that
observed for naive B cells.
Cell-surface class II-CLIP expression provides an indi-
rect measurement of surface class II-peptide expression
(11). GC and memory B cells displayed 50 and 30% less
class II-CLIP, respectively, than naive B cells (Fig. 2 B).
The heterogeneity observed for class II-CLIP levels among
the different tonsillar samples can be attributed to CLIP
binding of different class II alleles with varying affinities
(16). As expected, naive and memory B cells had reduced
cell-surface B7.1 and B7.2, and these molecules were sig-
nificantly increased on GC B cells (Fig. 2, C and D). Taken
together, the findings of increased cell-surface expression of
DR, B7.1, and B7.2 and decreased levels of surface ex-
pressed class II-CLIP on GC B cells support that GC B
cells are primed for optimal antigen presentation.
 
DO Expression Is Down-regulated in GC B Cells.
 
Since
the density of cell-surface class II-CLIP correlates with
augmented DM expression relative to DO expression (6, 8,
17), our observations suggested that GC B cells express ele-
vated DM levels or, alternatively, reduced DO levels. DO
and DM protein levels in tonsillar B cell subsets were ex-
amined by intracellular staining with mAbs to DO and
DM. These analyses showed that DO is significantly de-
creased in GC B cells relative to naive (
 
P
 
 
 
 
 
 0.0001) and
memory (
 
P
 
 
 
 
 
 0.0001) B cells (Fig. 3, A and B). Overall,
DO levels in GC B cells were reduced 60–90% relative to
the levels in naive B cells. Although DM also was decreased
in GC B cells relative to naive and memory B cells, the de- 
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crease in DM levels (0–35% of naive) was not nearly so
dramatic as that observed for DO (Figs. 3, A and C). In-
deed, in 4 out of 15 tonsillar specimens, DM levels were
not decreased in GC B cells. Taken together, these data
demonstrate that DO protein levels are modulated during
B cell differentiation.
 
Biochemical Analysis of DO Protein Levels in GC and Naive
B Cell Subsets.
 
To quantitate the degree of altered DO
(and DM) expression in GC B cells, we sorted GC and na-
ive B cells from five tonsillar samples (Fig. 4 A). DO
 
 
 
 and
DM
 
 
 
 protein levels were measured for the two popula-
tions by quantitative Western blotting (Fig. 4 B). In the
specimens evaluated, GC B cells had 3–29% of DO
 
 
 
 levels
expressed by naive B cells, whereas DM
 
 
 
 levels ranged
from 13 to 71% of the naive levels (Fig. 4 C). In each case,
DO
 
 
 
 protein levels decreased more in GC B cells than did
DM
 
 
 
. These biochemical analyses are consistent with the
results for DO and DM expression obtained by intracellular
staining and flow cytometry (Fig. 3). Since most if not all
DO is associated with DM in human B cells (5), these data
indicate that naive B cells bear a greater proportion of DM
complexed with DO relative to GC B cells, which express
 
more free DM. Free DM in GC B cells would afford more
efficient class II-peptide loading, as is suggested by the low
levels of class II-CLIP, and would promote the capacity of
GC B cells to function as APCs.
 
DR
 
 
 
CLIP Ratios Directly Correlate with DM/DO Ratios in
B Cell Subsets.
 
To estimate the efficiency of MHC class II
peptide loading, the ratio of cell-surface DR relative to
cell-surface class II-CLIP (DR/CLIP) in the tonsillar B cell
subsets was determined. A low DR/CLIP ratio indicates a
low efficiency of peptide loading, whereas a high ratio sug-
gests efficient peptide loading. The analyses revealed that
GC B cells have high DR/CLIP ratios (average 4.2),
whereas naive and memory B cells have low DR/CLIP ra-
tios (average 1.1 and 1.2, respectively; Fig. 2 E). The trend
for DR/CLIP ratios essentially was identical among all ton-
sillar samples studied, and the differences were highly sig-
nificant (Fig. 2 E).
The high DR/CLIP ratios observed in GC B cells sug-
gested that DM/DO ratios should be similarly elevated in
GC B cells. Indeed, as shown in Fig. 2 F, GC B cells had the
highest ratio of DM relative to DO (1.5 to 5.7), whereas na-
ive and memory B cells demonstrated similar DM/DO ra-
Figure 1. Surface phenotype of B
cell subsets. T cell–depleted tonsillar
cells were stained with mAbs as indi-
cated and analyzed by three-color
flow cytometry. (A) Identification of
naive (IgD  CD38 ), GC (IgD 
CD38 ), and memory (IgG 
CD38 ) B cell subsets. (B) Histo-
grams indicate surface expression
(solid lines) of DR, class II-CLIP,
and B7.1 and B7.2 on naive, GC
and memory B cells, electronically
gated as defined in A. The MFI ob-
tained after staining with specific
mAb for the cell-surface marker of
interest less the MFI obtained with
an isotype control (dashed lines) is
shown on each histogram (specific
MFI). The bar graphs below each set
of histograms show plots of the three
distinct B cell subsets versus the spe-
cific MFI for each stain. N, naive;
GC, germinal center; M, memory. 
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tios (0.6 to 1.7). As expected, elevated DM/DO correlated
with high DR/CLIP in GC B cells (Fig. 2, compare E and
F). These analyses point to the functional consequence of
modulation of DO relative to DM in B cells. Cells that ex-
press high levels of DO, such as naive and memory cells,
have more class II-CLIP and, therefore, less class II-peptide
at the cell surface. On the other hand, cells with relatively
low levels of DO, such as GC B cells, have reduced class II-
CLIP and, thus, more class II-peptide that allows for pro-
ductive and efficient stimulation of T cells.
 
Mechanism for Decreased DO and DM Levels in GC B
Cells.
 
Two possible mechanisms to account for decreased
DO and DM in GC B cells are protein degradation and
transcriptional regulation. To determine if decreased DM
and DO in GC B cells resulted from decreased transcrip-
tion, we sorted naive and GC B cells and assessed DMA
and DOB transcription by real-time PCR. Expression of
DMB and DOA was not analyzed, since it has been shown
that these genes are regulated in a manner identical to
DMA (18). To normalize for differences in RNA concen-
trations, we determined the ratio of DMA message relative
to DOB message in naive and GC B cells for different sam-
ples. As shown in Fig. 5, there was no significant alteration
in the ratio of DMA message relative to that for DOB. We
conclude that transcriptional regulation of these genes is
not responsible for the reduced DO/DM ratio in GC B
Figure 2. GC B cells have the
phenotype of an efficient APC. Pu-
rified tonsillar B cells were analyzed
by FACS for cell-surface DR, class
II-CLIP, B7.1 and B7.2 on naive,
GC and memory B cell as in Fig. 1.
MFI levels for (A) DR, (B) class II-
CLIP, (C) and B7.1 and (D) B7.2 in
naive B cells was set at 100% and the
values obtained for GC and memory
B cells of the same specimen were
normalized to this value (Relative
Expression). (E) Ratio of cell surface
DR to Class II-CLIP in B cell sub-
sets based on specific MFI levels for
each stain in each subset. (F) Ratio
of intracellular DM to DO-specific
MFI in distinct B cell subsets based
on FACS analyses as in Fig. 3. Solid
bars represent the mean for all sam-
ples (n   15). Individual tonsils are
denoted by distinct symbols in all
analyses. The tonsil shown in Figs. 1
and 3 is denoted by  . The statisti-
cal significance of potential differ-
ences between B cell subsets was es-
tablished by the Student’s t test.
N.S., nonsignificant. 
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cells. Treatment of tonsillar B cells with protease inhibitors
as well as inhibitors of the vacuolar ATPase, has not yet
provided conclusive evidence that protein degradation is
the mechanism (unpublished data).
 
Discussion
 
The unique expression of DO in B cells, but not in den-
dritic cells or macrophages, suggests that DO may impact
the timing and efficiency of T cell–B cell interactions. Our
examination of the class II antigen-processing pathway in
naive, GC and memory B cells showed that GC B cells
down-modulate DO and, thus, express more DM than
DO. The functional significance of the modulation of DO
is evident from analyses of class II-CLIP on the surface of
these B cell subsets. GC B cells had significantly lower lev-
els of cell-surface class II-CLIP compared with that dis-
played on naive and memory B cells. These data suggest
that down-modulation of DO in GC B cells favors efficient
presentation of peptide antigen to CD4 T cells. Coupled
with expression of high levels of the costimulatory mole-
cules, B7.1 and B7.2, it is clear that GC B cells are poised
for efficient T cell stimulation. Such interactions would
provide survival signals required during B cell positive se-
lection in the germinal center.
Our findings that GC B cells have reduced DO and sur-
face class-CLIP and elevated class II-peptide, B7.1 and
B7.2 support that these cells are optimally active APCs.
Since DO inhibits or alters DM-mediated peptide loading,
these findings suggest that antigen processing and presenta-
tion by B cells is more active in GC B cells relative to naive
B cells. Indeed, several studies have demonstrated that na-
ive B cells are poor APCs, which was, however, attributed
to the lack of expression of costimulatory molecules (19).
Our data suggest that elevated DO expression in naive B
cells contributes to the inefficient presentation capabilities
of naive B cells. As dendritic cells, rather than naive B cells,
are responsible for activation of antigen-specific T helper
Figure 3. DO expression is down-modulated in
GC B cells. Tonsillar B cells were stained with
mAbs to IgD and CD38 or IgG and CD38, perme-
abilized, and stained with mAbs specific for DO
(Mags.DO5-FITC) and DM (MaP.DM1-FITC).
(A) Histograms show intracellular levels of DO and
DM (solid lines) or of an isotype-matched control
(dashed lines) in electronically gated B cell subsets
from a representative sample. Specific MFI for each
protein of interest is shown on the histograms. Bar
graphs below each set of histograms shows the MFI
for each protein in the B cell subsets. Summary of
intracellular levels of DO (B) and DM (C) in all
samples. The tonsillar specimen shown in A and Fig.
1 is denoted by  . The Student’s t test was applied
to establish the significance of observed differences
between the specific MFI. N.S., nonsignificant. 
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cells during initiation of antibody responses (20–22), ex-
pression of DO in naive B cells may skew the activation of
antigen-specific T cells during the initiation of immune re-
sponses onto dendritic cells.
The precise physiological role for DO in vivo remains
unknown. Studies to date have shown that DO is an inhibi-
tor of DM-mediated peptide exchange, perhaps in a pH-
dependent manner (4, 6–9, 17). In addition, studies in the
murine system have shown that H2-O (mouse homologue
of DO)–deficient B cells present endocytosed antigens more
efficiently than H2-O–sufficient cells, and that presentation
of antigens via surface immunoglobulin on B cells results in
equal or slightly improved presentation of antigens when
H2-O is present (7). Collectively, these results suggest that
DO alters or modifies peptide loading of class II molecules
and function to skew antigen presentation toward proteins
that have been internalized by surface immunoglobulin.
Our results demonstrate that DO protein levels are actively
modulated in vivo during B cell development, resulting in
efficient and productive antigen presentation by GC B cells.
However, it is likely that other factors such as increased pro-
tease expression or modulation of endocytic compartments
may also contribute to increased presentation capabilities of
GC B cells (23). We conclude that, down-regulation of DO
in GC B cells may provide a mechanism by which GC B
cells foster their own interaction with antigen-specific T
cells and survive the process of B cell positive selection.
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Figure 4. DO expression is increased in naive B cells relative to GC B
cells (A) Tonsillar B cells were sorted to separate naive (IgD  CD38 )
and GC (IgD  CD38 ) B cells. (B) Detergent lysates from sorted B cells
were separated by SDS-PAGE, transferred to membranes, and probed
with antibodies to the cytoplasmic tails of DO  (R.DOB/c) and DM 
(R.DMB/c). Pala and T2 cells were included as positive and negative
controls, respectively. To demonstrate proportional loading, each blot
was also probed with an antiserum specific for calnexin. (C) Summary of
DO  and DM  levels in GC B cells relative to naive B cells for five
different tonsil samples. Tonsils used for this analysis are denoted in Figs.
2 and 3 as follows: A ( ); B ( ); C ( ); D ( ); E ( ).
Figure 5. Decreased DO expression in GC B cells is not due to tran-
scriptional regulation. Message levels for DMA and DOB in naive and
GC B cells were assessed by Real-time PCR. The graph shows the ratio
of DMA message relative to DOB message in naive or GC B cells for four
samples. Tonsils used for this analysis are denoted in Figs. 2 and 3 as follows:
A ( ); B ( ); C ( ); D ( ).  
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